Blog

When a Paediatric Extension Is Not Granted: The Mylotarg Opinion and Article 46 Data

In October 2026 the CHMP did not recommend extending Mylotarg (gemtuzumab ozogamicin) to children aged 1 to under 18 with newly diagnosed AML. Even so,[…]

Withdrawn Extension Applications: Reading Ibrance and Truqap in October 2026

The October 2026 CHMP highlights record two withdrawn applications for extensions of indication, for Ibrance (palbociclib) in HER2-positive breast cancer maintenance and Truqap (capivasertib) in[…]

CHMP Re-examination: What Happens After a Negative Opinion

In October 2026 the CHMP confirmed its refusal of Yartemlea (narsoplimab) following re-examination. The case is a useful reminder of how the re-examination procedure works[…]

Oral GLP-1 Receptor Agonists: The Foundayo Opinion and Questions for Quality and Market Access

The CHMP has recommended Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for weight management and type 2 diabetes in adults. A tablet in this[…]

Phased Review and the Cancer Medicines Pathfinder: A Faster Route to a Centralised Opinion

In July 2026 EMA announced a phased (rolling) review of daraxonrasib for metastatic pancreatic cancer. In October the CHMP recommended it as Rasonque. The case[…]

October 2026 CHMP Opinions: Six New Medicines and What They Signal for Sponsors

The CHMP meeting of 12–15 October 2026 ended with six positive opinions for new medicines, five extensions of indication and one confirmed refusal. For anyone[…]

Choosing a Medicine Name: Getting an Invented Name Past the EMA Name Review Group

An invented name is the first thing a prescriber, pharmacist and patient will see, and it is also a patient-safety question. For centrally authorised medicines,[…]

Renewals and the Sunset Clause: Keeping a Marketing Authorisation Alive

A marketing authorisation is not a permanent asset by default. It must be renewed once, after five years, and it can lapse in practice if[…]

On-Hold Botanical Health Claims: Why They Remain a Compliance Risk

For well over a decade, claims for botanical ingredients have sat in an unresolved state under the EU nutrition and health claims rules. Using them[…]

Ashwagandha in Food Supplements: A Patchwork of National Positions

Ashwagandha remains lawful in food supplements at EU level, but national positions differ widely and the safety debate is unresolved. Companies selling it across borders[…]

1 … 4 5 6 7 8 … 34